ColonCancerCheck Mailed Invitations: An Evaluation

NCT02364895 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75317

Last updated 2015-02-18

No results posted yet for this study

Summary

This study evaluates effectiveness of mailed invitations for colorectal cancer screening among screen-eligible Ontarians who are due for screening. The study will evaluate the effectiveness of mailed invitations in general (compared to no invitation) but will also determine if new invitation letters (2 letters for male, 1 letter for females) are more effective than current invitation letters used by the ColonCancerCheck program.

Conditions

  • Colorectal Disorders

Interventions

OTHER

Males control group: Deferred letter

This letter will be sent 6 months after index (mailing) date

OTHER

Males Group 1: Current CCC invitation letter

This letter is currently used by the program in 50-54 year olds

OTHER

Males Group 2: New letter with neutral gender content

Unisex letter

OTHER

Males Group 3: New letter with male-specific content

New letter tailored for men

OTHER

Females control group: Deferred letter

This letter will be sent 6 months after index (mailing) date

OTHER

Females Group 1: Current CCC invitation letter

This letter is currently used by the program in 50-54 year olds

OTHER

Females Group 2: New letter with neutral gender content

Unisex letter

Sponsors & Collaborators

  • Cancer Care Ontario

    collaborator OTHER
  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Jill Tinmouth, MD PhD FRCPC · Sunnybrook Health Sciences Centre, Cancer Care Ontario

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
55 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-05-31
Completion
2014-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02364895 on ClinicalTrials.gov